A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
Plain-language summary
This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.
Who can join (key eligibility)
- Age 18 Years to 65 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
C-BEAM Regimen (DRUG): Chidemide，carmustine, etoposide, cytarabine, and melphalan | BEAM Regimen (DRUG): carmustine, etoposide, cytarabine, and melphalan
C-BEAM Regimen, BEAM Regimen
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details